Jun 20, 2025
Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
May 28, 2025
Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications
Apr 28, 2025
Halozyme to Report First Quarter 2025 Financial and Operating Results
Apr 10, 2025
Halozyme Announces FDA Approval of argenx's VYVGART® Hytrulo Prefilled Syringe Co-Formulated with ENHANZE® for Self-Injection for Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy
Apr 09, 2025
European Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility
Apr 07, 2025
European Commission Approves Subcutaneous RYBREVANT® (amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer
Dec 30, 2024
Halozyme Announces argenx's VYDURA with ENHANZE® was Granted Regulatory Approval in Japan for Chronic Inflammatory Demyelinating Polyneuropathy
Dec 30, 2024
Halozyme Announces FDA Approval of Bristol Myers Squibb's Opdivo Qvantig(TM) with ENHANZE® for Subcutaneous Use in Most Previously Approved Adult Solid Tumor Opdivo® (nivolumab) Indications
Oct 23, 2024
Halozyme to Report Third Quarter 2024 Financial and Operating Results
Sep 13, 2024
Halozyme Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO(TM) with ENHANZE® for People with Relapsing and Primary Progressive Multiple Sclerosis
Aug 28, 2024
Halozyme to Present at Upcoming Investor Conferences
Aug 06, 2024
HALOZYME REPORTS SECOND QUARTER 2024 FINANCIAL AND OPERATING RESULTS
Jul 23, 2024
Halozyme to Report Second Quarter 2024 Financial and Operating Results
Jun 04, 2024
Halozyme to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
May 08, 2024
Halozyme to Participate in Upcoming Investor Conferences
Apr 25, 2024
Mahesh Krishnan Elected to Halozyme's Board of Directors
Apr 23, 2024
Halozyme to Report First Quarter 2024 Financial and Operating Results
Feb 20, 2024
HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL AND OPERATING RESULTS
Feb 08, 2024
Halozyme To Report Fourth Quarter and Full Year 2023 Financial and Operating Results
Jan 16, 2024
Halozyme Announces Takeda Receives FDA Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)